Table 2. Alterations in IGA and EASI scores and area of lesion to BSA (*: 95% confidence interval) measured until week 24.

	Pimecrolimus	Desonide	p-value
IGA score at week 1	2.9 (2.4–3.2)*	2.4 (2.0–2.9)	0.146
IGA score at week 2	2.5 (1.9–3.0)	2.0 (1.6–2.5)	0.185
IGA score at week 4 or open	2.4 (1.8–3.1)	2.1 (1.6–2.6)	0.346
IGA score at week 24, open-label phase	1.5 (1.0–2.0)	1.6 (1.3–2.0)	0.641
EASI score at week 1	8.3 (6.3–10.3)	5.1 (3.9–6.3)	0.007
EASI score at week 2	6.3 (4.4–8.1)	3.0 (2.1–4.0)	0.003
EASI score at week 4 or open	7.0 (4.4–9.6)	3.5 (2.1–4.0)	0.016
EASI score at week 24, open-label phase	3.1 (1.7–4.6)	2.3 (1.4–3.3)	0.340
Area of lesion to BSA at week 1; %	19.4 (15.0–23.8)	14.8 (10.9–18.8)	0.118
Area of lesion to BSA at week 2; %	13.7 (9.3–18.1)	9.1 (5.8–12.5)	0.097
Area of lesion to BSA at week 4 or open; %	13.6 (8.3–18.8)	8.7 (6.1–11.3)	0.093
Area of lesion to BSA at week 24, open-label phase; %	5.4 (3.2–7.6)	5.6 (2.8–8.5)	0.906

IGA: Investigator's Global Assessment total eosinophil;

EASI: Eczema Area and Severity Index;

BSA: Body Surface Area.